Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparative potential of Simvastatin, Rosuvastatin and Fluvastatin against bacterial infection: an in silico and in vitro study

  • 53 Accesses

  • 5 Citations


In the current investigation, we have compared the potential of statin drugs (Simvastatin, Rosuvastatin and Fluvastatin) as potential anti-bacterial agent by conducting in silico, in vitro and ex vivo studies. In silico study was conducted to check the interaction of statin drugs towards various targets of bacteria. The percentage growth retardation, bacterial growth kinetics, MIC determination, post antibiotic effect and biofilm formation assay were conducted to check the anti-bacterial effect of statin drugs under in vitro conditions. Finally, MTT assay was used to check the percentage of immune cell viability after Simvastatin treatment. Docking studies have revealed good interaction of Simvastatin, Rosuvastatin and Fluvastatin towards various targets of bacterial strains as that of the internal ligand. Simvastatin has shown good antibacterial activity against S. aureus, B. pumilus, P. aeruginosa and S. enterica as compared to Rosuvastatin and Fluvastatin. In vitro results have shown concentration and time dependent inhibition of bacterial growth by Simvastatin in concentration range of 64–256 μg/ml. Finally, MTT assay have shown non-cytotoxic effect of Simvastatin against adaptive immune system. In conclusion, Simvastatin could be a potential candidate as an anti-bacterial agent against a wide range of bacterial infections. However, further studies are required to check its complete role before starting phase I clinical trial.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. Bannister RM, Wanderlay WC, Brew J (2010) Treatment of microbial infections. Biocopea Limited. U.S. Patent Application. 13/509:534

  2. Bradbury BJ, Pucci MJ (2008) Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 8:574–581.

  3. Caldwell JR, Cluff LE (1974) Adverse reactions to antimicrobial agents. JAMA 230:77–80.

  4. Chow OA, von Köckritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL (2010) Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8:445–454.

  5. Cohen ML (1992) Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050–1055.

  6. Craig WA (1996) Post-antibiotic effect. Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins Co., Baltimore

  7. Davignon J, Jacob RF, Mason RP (2004) The antioxidant effects of statins. Coron Artery Dis 15:251–258.

  8. Donowitz GR, Mandell GL (1988) Beta-lactam antibiotics. N Engl J Med 318:490–500.

  9. Eliopoulos GM, Roberts MC (2003) Tetracycline therapy: update. Clin Infect Dis 36:462–467.

  10. Graziano TS, Cuzzullin MC, Franco GC, Schwartz-Filho HO, de Andrade ED, Groppo FC (2015) Statins and antimicrobial effects: simvastatin as a potential drug against Staphylococcus aureus biofilm. PLoS ONE 10:0128098.

  11. Grewal GK, Rawal RK (2014) Molecular docking studies on (hetero) arlylidene (4-substituted-thiazol-2-yl) hydrazines as MAO-B inhibitors. Asian J Biomed Pharm Sci 4:56

  12. Gupta M, Kumar A (2019) Comparison of minimum inhibitory concentration (MIC) value of statin drugs: a systematic review. Anti-Infect Agents.

  13. Gupta M, Sharma R, Kumar A (2018a) Docking techniques in pharmacology: how much promising? Comput Biol Chem 76:210–217.

  14. Gupta M, Kant K, Sharma R, Kumar A (2018b) Evaluation of in silico anti-parkinson potential of β-asarone. Cent Nerv Syst Agents Med Chem 18:128–135.

  15. Hawser S, Lociuro S, Islam K (2006) Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71:41–948.

  16. Hennessy E, Adams C, Reen FJ, O’Gara F (2016) Is there potential for repurposing statins as novel antimicrobials? Antimicrob Agents Chemother 60:5111–5121.

  17. Jacobson TA (2006) Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 97:S44–S51.

  18. Jaiswal S, Duffy B, Jaiswal AK, Stobie N, McHale P (2010) Enhancement of the antibacterial properties of silver nanoparticles using β-cyclodextrin as a capping agent. Int J Antimicrob Agents 36:280–283.

  19. Jouneau S, Bonizec M, Belleguic C, Desrues B, Brinchault G, Galaine J (2011) Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis. PLoS ONE 6:22655.

  20. Kamińska M, Aliko A, Hellvard A, Marczyk A, Mydel P (2017) Effects of statins on multispecies oral biofilm. J Oral Microbiol 9:1325249.

  21. Kohanski MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 8:423

  22. Kumar A, Sasmal D, Sharma N (2014) Deltamethrin induced an apoptogenic signalling pathway in murine thymocytes: exploring the molecular mechanism. J Appl Toxicol 34:1303–1310.

  23. Kumar A, Sasmal D, Sharma N (2018) Mechanism of deltamethrin induced thymic and splenic toxicity in mice and its protection by piperine and curcumin: in vivo study. Drug Chem Toxicol 41:33–41.

  24. Langfield RD, Scarano FJ, Heitzman ME, Kondo M, Hammond GB, Neto C (2004) Use of a modified microplate bioassay method to investigate antibacterial activity in the Peruvian medicinal plant Peperomiagalioides. J Ethnopharmacol 94:279–281.

  25. Lefer DJ (2011) Statins as potent anti-inflammatory drugs. Circ Res 106:2041–2042.

  26. Mach F (2002) Toward a role for statins in immunomodulation. Mol Interv 2:478.

  27. Masadeh M, Mhaidat N, Alzoubi K, Al-azzam S, Alnasser Z (2012) Antibacterial activity of statins: a comparative study of atorvastatin, Simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob 11:13–18.

  28. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D (2011) The cost of drug development: a systematic review. Health Policy 100:4–17.

  29. Mullin R (2014) Cost to develop new pharmaceutical drug now exceeds $2.5 B. Sci Am 24:1–2

  30. NCCLS (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7eA7. Clinical and laboratory Standards Institute, Wayne

  31. Oprea TI, Mestres J (2012) Drug repurposing: far beyond new targets for old drugs. AAPS J 14:759–763.

  32. Raja AF, Ali F, Khan IA, Shawl AS, Arora DS, Shah BA (2011) Antistaphylococcal and biofilm inhibitory activities of acetyl-11-keto-beta-boswellic acid from Boswelliaserrata. BMC Microbial 11:54.

  33. Stancu C, Sima A (2001) Statins: mechanism of action and effects. J Cell Mol Med 25:378–387.

  34. Tabish SA, Syed N (2015) The future of humanity and microbes: impact of emerging infectious diseases on global health and economies. Int J Pharm Sci Res 4:2427–2442

  35. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev.

  36. Thangamani S, Mohammad H, Abushahba MF, Hamed MI, Sobreira TJ, Hedrick VE (2015) Exploring Simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci Rep 5:16407

  37. Tobinick EL (2009) The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 22:119–125

  38. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein–ligand docking using GOLD. Proteins Struct Funct Bioinf 52:609–623.

  39. Who G (2013) WHO methods and data sources for global burden of disease estimates 2000–2011. Department of Health Statistics and Information Systems, Geneva

  40. Wu WS, Chen CC, Chuang YC, Su BA, Chiu YH, Hsu HJ (2013) Efficacy of combination oral antimicrobial agents against biofilm-embedded methicillin-resistant Staphylococcus aureus. J Microbiol Immunol Infect 46:89–95.

  41. Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ (2017) Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function. Cell Host Microbe 22:757–765.

Download references


Authors are thankful to Shri. Parveen Garg, Chairman, ISFCP, for providing research facility. Authors are thankful to Mr. Saurabh Bhandari, Assistant Professor, Microbiology Division, ISFCP, Moga for providing support in completion of this research work. Authors are also thankful to Mr. Anshul Ruhela, B.Tech., Ansal University, for graphic enhancement of images. Author, Anoop Kumar is also thankful to Dr. S.J.S. Flora, Director, NIPER, Raebareli for their constant support and motivation.

Author information

Correspondence to Anoop Kumar.

Ethics declarations

Ethical statement

Animal house is registered with the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India. Registration number: 816/Po/Re/S/04/CPCSEA.

Conflict of interest

This manuscript described has not been published before; not under consideration for publication anywhere else; and has been approved by all co-authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gupta, M., Sharma, R. & Kumar, A. Comparative potential of Simvastatin, Rosuvastatin and Fluvastatin against bacterial infection: an in silico and in vitro study. Orient Pharm Exp Med 19, 259–275 (2019).

Download citation


  • Simvastatin
  • Rosuvastatin
  • Fluvastatin
  • Docking study
  • Bacterial infections
  • Antibiotics